Loading patent…
AssigneeGenbioma Aplicaciones, S.L.
InventorsGregorio Sanzol Baztan, Miguel Ángel Barajas Vélez, Ignacio José Encío Martínez, Jesús V. Díaz Cano, María Oneca Agurruza, Ricardo Sánchez-Valverde Amatriain, Miriam Araña Ciordia, Jorge Sánchez-Valverde Amatriain, Josune Ayo Martínez
Estimating the term…
The present application refers to oral compositions comprising an effective amount of a Pediococcus acidilactici strain for use in regulating blood glucose levels, as well as for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition. The application also refers to Pediococcus acidilactici CECT 9879, Pediococcus acidilactici CECT 9889 and Pediococcus acidilactici CECT 9967, and to these strains for use as probiotics, medicaments and for regulating blood glucose levels, as well as for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition.
A method for regulating blood glucose levels in an animal in need thereof comprising orally administering to said animal an effective amount of Pediococcus acidilactici CECT 9879, wherein the effective amount is 104 to 1012 bacteria per dose, per day, or per 24-hour period.
A method for the prevention and/or treatment of hyperglycemia and/or a hyperglycemia-related condition selected from the group consisting of impaired fasting glycemia (IFG), impaired glucose tolerance (IGT), postprandial hyperglycemia, glucose intolerance, Type II pre-diabetes, and gestational diabetes in an animal in need thereof, the method comprising orally administering to said animal an effective amount of Pediococcus acidilactici CECT 9879, wherein the effective amount is 104 to 1012 bacteria per dose, per day, or per 24-hour period.
Dependencies are inferred from the claim text.